More than 170 clinical trials are open at Providence Cancer Center
June 2017
Providence Cancer Center is currently conducting more than 170 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches. Please see the links below for studies in specific disease areas.
New studies for head and neck cancer patients
Currently, 13 oral, head and neck cancer studies are open at Providence Cancer Center.
Adoptive T-cell transfer powers up immune system
Adoptive T-cell transfer therapy is emerging as one of the
most effective treatments to date for people with advanced melanoma. Now, for the first time, this treatment is available to patients with advanced head and neck cancers through a
clinical trial at Providence Cancer Center.
In this therapy, tumor-infiltrating lymphocytes (TILs) are extracted from a patient’s own tumor, multiplied as much as a trillion-fold in the lab. This expanded army of TILs is then re-infused back into the patient to increase the power of the immune system to fight the cancer. As part of this study, patients also receive interleukin-2.
To refer patients to any of these studies, call Providence Cancer Center’s Clinical Trials office at 503-215-2614 or visit
oregon.providence.org/clinical-trials.
Providence Oral, Head and Neck Cancer Clinic
The
Providence Oral, Head and Neck Cancer Clinic offers world-class care for patients with benign and malignant tumors of the oral cavity (mouth), tongue, pharynx (throat), larynx (voice box), nose, paranasal sinuses, salivary glands and thyroid gland, as well as tumors at the skull base. Our medical and surgical oncology teams work collaboratively to start patients on treatment regimens very quickly.
The clinic’s co-directors – medical oncologist
Rom Leidner, M.D., and oncological surgeon
R. Bryan Bell, M.D., D.D.S., FACS – are innovative leaders committed to elevating the current standard of care for oncology patients by offering advancements such as pre-operative immunotherapy. Their aim is to improve surgical outcomes and reduce the risk of recurrence.
